Cambridge Cognition and Oura launch large-scale brain health study integrating cognition with wearable sleep and physiological data
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces a collaboration with ŌURA, maker of the world's leading smart ring, on a new institutional review board (IRB)-approved brain health study. Conducted through Oura Labs, an experimental…
Placing and subscription raising approximately £1.12 million, total voting tights and PDMR dealings
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce that following the announcement of its interim results for the six months ended 30 June 2025 earlier this morning and in response to shareholder demand, it has raised gross proceeds of approximately £1.12…
Cambridge Cognition investment, Monument Therapeutics, achieves positive Phase I results for novel schizophrenia treatment
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved positive topline results from its Phase I clinical trial of MT1988, a novel treatment for cognitive impairment associated with schizophrenia …
SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers
This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from SIRS 2025.
Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial. The initial contract, starting in 2025 and running through to 2031, is valued at approximately £1…
Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase 3 clinical trials in adolescents with Major Depressive Disorder (MDD). Both contracts are set to commence this year, with the first…
Cambridge Cognition selected by the University of Oxford as a cognitive assessment partner for the ISAP study
Cambridge Cognition is pleased to announce that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid Positivity (“ISAP”) study. As a consequence Cambridge Cognition expects to receive validation data for its voice-based solution, NeuroVocalixTM.
Cambridge Cognition completes spin-out of Monument Therapeutics
Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system (CNS) disorders.
Cambridge Cognition wins new £2.2 million contract for at-home cognitive testing in a virtual clinical trial
Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021.
Cambridge Cognition awarded contracts totalling £1.4m for digital health and wearable device provision for clinical trials
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a series of contracts from a global pharmaceutical company to provide specialist clinical trial management services.
Cambridge Cognition provides cognitive assessments in an at-home clinical trial
Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial. The contract is worth approximately £0.5 million.
CANTAB technology selected for world’s largest dementia study
Cambridge Cognition Holdings PLC (AIM: COG), the digital neuroscience company which develops and markets software products to assess brain health, is pleased to announce its partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.
New product aims to improve workplace mental health
The digital neuroscience company Cambridge Cognition Holdings PLC (AIM: COG) is pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.
Cambridge Cognition and University of Bristol partnership to tackle mental health need
The digital neuroscience company Cambridge Cognition Holdings PLC (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.
New client signs with Cognition Kit software
Digital neuroscience company, Cambridge Cognition Holdings PLC, (AIM: COG) has announced a new $0.5m contract with a major pharmaceutical company for the use of its Cognition Kit digital health software in a clinical trial.
CANTAB Recruit contracts show strong growth for Cambridge Cognition
Cambridge Cognition Holdings PLC, (AIM: COG) the digital neuroscience company which develops and markets software products to assess brain health, is pleased to announce that its CANTAB Recruit software is now established in two major Phase III trials with one of the early adopters increasing its contract value twenty-four fold in the first year of use, totalling over £1.2 million.
Cambridge Cognition announces major contract win and funding award
The digital neuroscience company Cambridge Cognition Holdings PLC, (AIM: COG) which develops and markets software products to improve brain health, is pleased to announce the award of a major new pharmaceutical clinical trial contract and a Digital Health Catalyst grant from Innovate UK.
Cambridge Cognition unveils the first wearable for monitoring mental health
Cambridge Cognition shows its groundbreaking mental health wearable Cognition Kit™ for the first time at the Neurotech Investing Conference in Boston this week.
Cambridge Cognition ends the year on a high note
Cambridge Cognition Holdings plc, a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m.
30 years on, CANTAB inventors herald the dawn of a new era in neuroscience
Three decades ago two emerging neuroscientists, Barbara Sahakian and Trevor Robbins from University of Cambridge, received a grant to fund their development of the Cambridge Neuropsychological Automated Test Battery or CANTAB™.
New Alzheimer’s assessment product to accelerate development of treatments
Reliable cognitive measures for patients with Alzheimer's disease are essential when testing potential new drug interventions. The high attrition rate in Alzheimer’s disease clinical trials highlights the need for more sensitive analytical tools to be used throughout the drug development process.
Cambridge Cognition product exceeds £1m sales in first nine months
Cambridge Cognition today announces that sales of its Cantab Connect CTIS-Abuse Liability have exceeded £1 million ($1.5 million) in its first nine months from launch.
Cambridge Cognition opens US office
Cambridge Cognition has announced the opening of a US office in Salt Lake City, Utah, headed by former Baxter and Myriad executive Bill Rusconi to meet growing demand from both existing and new North American customers.
Cambridge Cognition wins significant contracts
Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in drug development, announces that it has now signed contracts with various leading pharmaceutical companies for eight human abuse and liability studies worth a total of approximately £710,000.
Cognitive safety assessment products launched on Cantab Connect
Cambridge Cognition has announced the launch of the first two iPad-tablet products on its new cloud computing Cantab Connect platform for use in clinical trials. Rapid iPad assessment paves the way for faster and more accurate decision making on cognitive safety and abuse potential of drug treatments.